Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Frontiers in Psychiatry|October 18, 2021
Examining Differences in Fear Learning in Patients With Obsessive-Compulsive Disorder With Pupillometry, Startle Electromyography and Skin Conductance ResponsesDorothee Pöhlchen, Marthe Priouret, Miriam S Kraft, et al.
Annales De Chirurgie Plastique Et Esthetique|November 13, 2025
[Rare breast tumors]E Laas, L Darrigues, J-P Binder, et al.
Journal of Sleep Research|December 15, 2023
The utility of wearable headband electroencephalography and pulse photoplethysmography to assess cortical and physiological arousal in individuals with stress-related mental disordersBorbala Blaskovich, Esteban Bullón-Tarrasó, Dorothee Pöhlchen, et al.
Behaviour Research and Therapy|April 18, 2020
No robust differences in fear conditioning between patients with fear-related disorders and healthy controlsDorothee Pöhlchen, Laura Leuchs, Florian P Binder, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 25, 2021
Structural correlates of trauma-induced hyperarousal in miceJulia Ruat, Daniel E Heinz, Florian P Binder, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|October 7, 2022
The 3114: A new professional helpline to swing the French suicide prevention in a new paradigmC-E Notredame, M Wathelet, M Morgiève, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumabD Arnold, C S Fuchs, J Tabernero, et al.
Journal of Hepatology|September 9, 2014
Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trialCurtis K Argo, James T Patrie, Carolin Lackner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 14, 2016
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapyM Moore, S Gill, T Asmis, et al.
Pageof 10